$261.3 M

MIRN Mkt cap, 31-Aug-2018

$254 K

Mirna Therapeutics Revenue Q2, 2018
Mirna Therapeutics Net income (Q2, 2018)-14.6 M
Mirna Therapeutics EBIT (Q2, 2018)-15.4 M
Mirna Therapeutics Cash, 30-Jun-201826.6 M

Mirna Therapeutics Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017

Revenue

2.4m

R&D expense

18.9m13.9m30.3m

General and administrative expense

6.1m8.1m12.9m

Operating expense total

25.0m26.6m43.3m

EBIT

(40.8m)

EBIT margin, %

(1670%)

Interest expense

57.0k

Interest income

44.0k350.0k

Net Income

(25.0m)(26.3m)(40.4m)

Quarterly

USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q3, 2017Q1, 2018Q2, 2018

Revenue

111.0k354.0k254.0k

R&D expense

4.5m3.7m3.4m9.0m8.4m10.9m

General and administrative expense

1.6m2.1m2.0m1.9m3.2m3.6m4.7m

Operating expense total

6.2m6.7m5.7m5.3m12.2m12.0m15.6m

EBIT

(12.1m)(11.6m)(15.4m)

EBIT margin, %

(10878%)(3287%)(6044%)

Interest expense

8.0k7.0k14.0k12.0k

Interest income

82.0k93.0k97.0k

Net Income

(6.2m)(6.6m)(5.6m)(5.4m)(11.9m)(11.2m)(14.6m)

Mirna Therapeutics Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017

Cash

89.7m16.4m58.4m

Inventories

793.0k882.0k

Current Assets

90.5m61.4m88.6m

PP&E

375.0k354.0k9.8m

Total Assets

90.9m64.2m99.7m

Accounts Payable

3.7m361.0k2.7m

Current Liabilities

5.9m2.8m9.0m

Non-Current Liabilities

5.6m

Total Liabilities

3.8m

Additional Paid-in Capital

161.5m163.1m156.7m

Retained Earnings

(76.5m)(102.8m)(71.7m)

Total Equity

85.0m60.4m

Financial Leverage

1.1 x1.1 x

Quarterly

USDQ3, 2015Q2, 2016Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

35.7m30.8m15.2m79.2m27.2m26.6m

Current Assets

36.1m73.5m48.1m98.2m127.9m145.3m

PP&E

266.0k1.2m13.0k13.7m14.6m

Total Assets

38.1m77.2m48.1m104.5m142.7m161.1m

Accounts Payable

2.2m1.5m47.0k956.0k1.3m1.1m

Current Liabilities

5.0m1.4m8.0m7.0m8.2m

Non-Current Liabilities

944.0k6.9m8.3m

Total Liabilities

3.7m1.4m

Additional Paid-in Capital

162.2m163.8m155.5m211.4m241.8m

Retained Earnings

(67.7m)(88.7m)(117.2m)(60.0m)(82.5m)(97.1m)

Total Equity

73.5m46.7m95.6m128.8m144.6m

Financial Leverage

1 x1 x1.1 x1.1 x1.1 x

Mirna Therapeutics Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

(25.0m)(26.3m)(40.4m)

Depreciation and Amortization

54.0k159.0k2.3m

Inventories

793.0k107.0k

Accounts Payable

3.7m(3.3m)4.1m

Cash From Operating Activities

(21.1m)(24.8m)

Purchases of PP&E

(251.0k)(1.7m)(2.6m)

Cash From Investing Activities

(251.0k)(48.5m)

Cash From Financing Activities

67.0k16.0k

Interest Paid

35.0k

Quarterly

USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(6.2m)(6.6m)(5.6m)(5.4m)(28.7m)(11.2m)(25.8m)

Depreciation and Amortization

1.3m681.0k1.2m

Accounts Payable

2.2m1.2m1.5m1.2m371.0k47.0k2.9m(3.0m)(1.3m)

Cash From Operating Activities

(22.0m)(13.0m)(23.8m)

Purchases of PP&E

(2.5m)(1.9m)(2.9m)

Cash From Investing Activities

19.7m(71.9m)(90.4m)

Cash From Financing Activities

66.9m53.6m82.4m

Interest Paid

22.0k14.0k25.0k

Mirna Therapeutics Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information

Mirna Therapeutics Operating Metrics

FY, 2016

Patents Issued

10

Patents Pending

42
Report incorrect company information